Axillary clearance forms part of the surgical armamentarium for the treatment of breast
cancer. Although the introduction of sentinel lymph node mapping and dissection has allowed
for the decreased use of axillary clearance, it remains a frequently performed operation.
Axillary clearance is associated with moderate postoperative pain.
We hypothesize that a continuous wound infusion of 0.2% Bupivacaine at 4ml/hr would provide
superior analgesia, when compared to standard opioid-based analgesia, in patients undergoing
axillary lymph node clearance surgery.